Literature DB >> 10699599

Management of patients with rising prostate-specific antigen after radical prostatectomy.

M Laufer1, C R Pound, M A Carducci, M A Eisenberger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10699599     DOI： 10.1016/s0090-4295(99)00465-3

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  13 in total

1.  Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.

Authors:  Orazio Schillaci; Ferdinando Calabria; Mario Tavolozza; Cristiana Ragano Caracciolo; Enrico Finazzi Agrò; Roberto Miano; Antonio Orlacchio; Roberta Danieli; Giovanni Simonetti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-10       Impact factor: 9.236

Review 2.  [PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?].

Authors:  M P Wirth; F M Engelhardt
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

3.  Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.

Authors:  Daniel Keizman; Marianna Zahurak; Victoria Sinibaldi; Michael Carducci; Samuel Denmeade; Charles Drake; Roberto Pili; Emmanuel S Antonarakis; Susan Hudock; Mario Eisenberger
Journal:  Clin Cancer Res       Date:  2010-10-26       Impact factor: 12.531

4.  Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging.

Authors:  Stefano Cirillo; Massimo Petracchini; Lorenza Scotti; Teresa Gallo; Annalisa Macera; Maria Cristina Bona; Cinzia Ortega; Pietro Gabriele; Daniele Regge
Journal:  Eur Radiol       Date:  2008-09-30       Impact factor: 5.315

Review 5.  PET imaging of recurrent and metastatic prostate cancer with novel tracers.

Authors:  Francesca V Mertan; Liza Lindenberg; Peter L Choyke; Baris Turkbey
Journal:  Future Oncol       Date:  2016-08-16       Impact factor: 3.404

6.  Decision-making Processes among Prostate Cancer Survivors with Rising PSA Levels: Results from a Qualitative Analysis.

Authors:  Megan Johnson Shen; Christian J Nelson; Ellen Peters; Susan F Slovin; Simon J Hall; Matt Hall; Phapichaya Chaoprang Herrera; Elaine A Leventhal; Howard Leventhal; Michael A Diefenbach
Journal:  Med Decis Making       Date:  2014-11-10       Impact factor: 2.583

7.  Phase II trial of GM-CSF in advanced prostate cancer.

Authors:  R Dreicer; W A See; E A Klein
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 8.  Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU).

Authors:  Pasquale Martino; Vincenzo Scattoni; Andrea B Galosi; Paolo Consonni; Carlo Trombetta; Silvano Palazzo; Carmen Maccagnano; Giovanni Liguori; Massimo Valentino; Michele Battaglia; Libero Barozzi
Journal:  World J Urol       Date:  2011-05-08       Impact factor: 4.226

Review 9.  Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Authors:  Francesca V Mertan; Matthew D Greer; Sam Borofsky; Ismail M Kabakus; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Top Magn Reson Imaging       Date:  2016-06

10.  Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.

Authors:  Wilfred D Stein; William Doug Figg; William Dahut; Aryeh D Stein; Moshe B Hoshen; Doug Price; Susan E Bates; Tito Fojo
Journal:  Oncologist       Date:  2008-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.